17:12 , Mar 16, 2018 |  BC Week In Review  |  Company News

Ionis looks to Akcea for speedy launch of inotersen

With an eye toward a commercialization race in hereditary transthyretin (TTR) amyloidosis (hATTR), Ionis Pharmaceuticals Inc. (NASDAQ:IONS) granted its majority-owned subsidiary Akcea Therapeutics Inc. (NASDAQ:AKCA) rights to inotersen on Thursday. While Ionis said on a...
01:29 , Mar 16, 2018 |  BC Extra  |  Company News

Ionis looks to Akcea for speedy launch of inotersen

With an eye toward a commercialization race in hereditary transthyretin (TTR) amyloidosis (hATTR), Ionis Pharmaceuticals Inc. (NASDAQ:IONS) granted its majority-owned subsidiary Akcea Therapeutics Inc. (NASDAQ:AKCA) rights to inotersen on Thursday. While Ionis said on a...